• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter International Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    9/9/24 9:05:07 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    bax-20240909
    0000010456false00000104562024-09-092024-09-090000010456exch:XCHIbax:CommonStock1.00PerValueMember2024-09-092024-09-090000010456exch:XNYSbax:CommonStock1.00PerValueMember2024-09-092024-09-090000010456exch:XNYSbax:GlobalNotes13Due2025Member2024-09-092024-09-090000010456exch:XNYSbax:GlobalNotes13Due2029Member2024-09-092024-09-09

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(D)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): September 9, 2024
    Baxter International Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of incorporation)
    1-444836-0781620
    (Commission File Number)(I.R.S. Employer Identification No.)
    One Baxter Parkway, Deerfield, Illinois
    60015
    (Address of principal executive offices)(Zip Code)
    (224)948-2000
    (Registrant’s telephone number, including area code)
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange
    NYSE Chicago
    1.3% Global Notes due 2025BAX 25New York Stock Exchange
    1.3% Global Notes due 2029BAX 29New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
    ☐ Emerging growth company
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:   ☐



    Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Appointment and Compensation of Jeffrey A. Craig as Director.
    On September 8, 2024, Baxter International Inc. (the “Company”) appointed Jeffrey (Jay) A. Craig to its Board of Directors (the “Board”). Mr. Craig has also been appointed to serve as a member of the Audit Committee. Upon his appointment to the Board, the number of directors constituting the Board increased to 12 directors.
    Mr. Craig is the former Chief Executive Officer and President of Meritor, Inc. (“Meritor”), a position he held from 2015 until 2021. He also served as Executive Chairman of the Board of Directors of Meritor in 2021 and a member of the Board of Directors of Meritor from 2015 until 2021. Prior to this, from 2014 to 2015, Mr. Craig was President and Chief Operating Officer, with oversight of Meritor’s business segments - Commercial Truck & Industrial and Aftermarket & Trailer. Prior to taking on the role of President and COO, Mr. Craig was Senior Vice President and President of Meritor’s Commercial Truck & Industrial segment from February 2013 to May 2014. He served as Senior Vice President and Chief Financial Officer at Meritor from February 2009 to January 2013 and held various leadership positions at Meritor since 2006. Before joining Meritor, Mr. Craig served as President and CEO of General Motors Acceptance Corp.’s (“GMAC”) Commercial Finance organization from 2001 to 2006. Prior to that, Mr. Craig was President and CEO of GMAC’s Business Credit division from 1999 until 2001. He joined GMAC as a general auditor in 1997 from Deloitte & Touche LLP, where he served as an audit partner. Mr. Craig currently serves as Chair of the Board of Directors of Hyliion Holdings Corp. and Chair of the Audit Committee of the Board of Directors for Arcosa Inc.
    Mr. Craig will be compensated for his service as a director pursuant to the Company’s Non-Employee Director Compensation Plan filed as Exhibit 10.36 to the Company’s Annual Report on Form 10-K filed on February 8, 2024 (the “2023 Form 10-K”), and will be eligible to participate in the Company’s Directors’ Deferred Compensation Plan filed as Exhibit 10.27 to the Company’s 2023 Form 10-K. In connection with joining the Board, Mr. Craig will be granted equity awards as compensation for a portion of his 2024 service (representing the period between September 8, 2024 and the Company’s 2025 annual meeting of stockholders) in an amount consistent with the awards granted annually to non-employee directors, prorated for the full calendar months to be served during such period in accordance with the terms of the Company’s Non-Employee Director Compensation Plan. A description of the Company’s non-employee director compensation arrangements can be found in the section titled “Proposal 1. Election of Directors-Director Compensation” in the Company’s definitive proxy statement for its 2024 annual meeting of stockholders filed on March 25, 2024 and is incorporated herein by reference.
    There are no arrangements or understandings between Mr. Craig and any other persons pursuant to which he was selected as a director, and there are no related party transactions, involving Mr. Craig that are required to be disclosed pursuant to Item 404(a) of Regulation S-K.
    A copy of the press release issued by the Company on September 9, 2024 announcing the appointment of Mr. Craig is attached hereto as Exhibit 99.1.



    Item 9.01 Financial Statements and Exhibits.
    (d)Exhibits.
    Exhibit NumberDescription
    99.1
    Press Release issued by Baxter International Inc., dated September 9, 2024
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)




    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    Date: September 9, 2024
    BAXTER INTERNATIONAL INC.
    By:/s/ Ellen K. Bradford
    Name:Ellen K. Bradford
    Title:Senior Vice President and Corporate Secretary


    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    More analyst ratings

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings

    New system offers a standardized and simplified alternative to traditional handwritten line labeling that supports safer medication administration Solution aims to streamline nursing workflow, helping to save clinician time and reduce likelihood of medication errors related to IV line labeling inconsistencies Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solution, at the 2026 American Organization for Nursing Leadership Conference. The IV Verify system is designed to streamline nursing workflows, save clinician time and support safer medication administration at the bedsid

    3/30/26 8:30:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Annual Meeting of Stockholders in Virtual Format

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2026 Annual Meeting. Online access to the 2026 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2026 Annual Meeting in person. The virtual format provides a safe, convenient and cost-effective experience to all stockholders and employees, regardless of location. Anyone who would like to attend the virtual 2026 Annual Meeting is encouraged to access the meeting in advance of the designated star

    3/25/26 4:30:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot

    Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare SettingsBELLEVUE, Wash. and DEERFIELD, Ill., March 25, 2026 /PRNewswire/ -- Pet Partners, the nation's leading organization dedicated to improving human health and well-being through therapy animal interactions, and the Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced a new partnership to expand access to therapy animal programs in healthcare settings across the country. The initiative will begin as a two-year pilot program in key regions, including Northern California, Up

    3/25/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Baxter International Inc.

    DEFA14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    3/23/26 8:52:56 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Baxter International Inc.

    DEF 14A - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    3/23/26 8:51:59 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    3/19/26 4:45:33 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, CAO and Controller Zielinski Anita A covered exercise/tax liability with 1,932 shares, decreasing direct ownership by 4% to 46,281 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    3/10/26 4:08:56 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Group Pres., ITT & Pharma. Soriano Maria Cecilia covered exercise/tax liability with 2,848 shares, decreasing direct ownership by 4% to 75,045 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    3/10/26 4:07:58 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP and General Counsel Rosenbloom David S. covered exercise/tax liability with 6,620 shares, decreasing direct ownership by 5% to 138,216 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    3/10/26 4:07:11 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and eve

    1/21/26 5:00:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30

    12/4/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities